Gray-market peptides pose risks due to lack of safety data and regulation.

The gray market for peptides operates with little official oversight. There is a significant lack of concrete safety data and clinical trial information. Consumers often rely on anecdotal evidence from informal online sources. This unregulated environment raises serious public health concerns.
This is an AI-generated summary. ShortSingh links to the original source for the complete article.


Discussion (0)
Log in to join the discussion and vote.
Log in